A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Irosustat (Primary) ; Aromatase inhibitors
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms IRIS; IRISv1-0
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 28 Jan 2016 Accrual to date is 100% according to United Kingdom Clinical Research Network record.